Cargando…

Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial

BACKGROUND: Non-small-cell lung cancer (NSCLC) is usually diagnosed at an advanced stage, and chemotherapy is the main treatment for this disease. Kanglaite injections (KLTi) have been widely used for the treatment of cancer in China. KLTi combined with chemotherapy could improve the short-term effi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Ruike, Zhang, Ying, Hou, Wei, Li, Jie, Zhu, Guanghui, Zhang, Xiaoxiao, Xu, Bowen, Wu, Zhe, Wang, Heping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966914/ https://www.ncbi.nlm.nih.gov/pubmed/33731199 http://dx.doi.org/10.1186/s13063-021-05169-w

Ejemplares similares

Evaluation of Efficacy and Safety for Kanglaite Injection in the Control of the Malignant Pleural Effusions via Thoracic Perfusion: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Zhu, Guanghui, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Sintilimab Combined with Chemotherapy Versus Chemotherapy Alone as the First-Line Treatment for Advanced Esophageal Cancer
por: Ye, Zhuo-Miao, et al.
Publicado: (2022)

Gene Differential Expression and Interaction Networks Illustrate the Biomarkers and Molecular Biological Mechanisms of Unsaponifiable Matter in Kanglaite Injection for Pancreatic Ductal Adenocarcinoma
por: Xu, Bowen, et al.
Publicado: (2022)

A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer
por: Cui, Hanzhi, et al.
Publicado: (2020)

Kanglaite Injection Combined with Chemotherapy versus Chemotherapy Alone for the Improvement of Clinical Efficacy and Immune Function in Patients with Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Wen, Jianxia, et al.
Publicado: (2020)

Aidi Injection, Compound Kushen Injection, or Kanglaite Injection: Which Is the Best Partner with Systemic Chemotherapy for Patients with HCC? A Network Meta-Analysis
por: Dou, Dou, et al.
Publicado: (2020)

Efficacy and safety of Kanglaite injection combined with chemotherapy for colorectal cancer: A protocol for systematic review and meta-analysis
por: Mao, Weili, et al.
Publicado: (2020)

First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis
por: Cao, Xueqiong, et al.
Publicado: (2022)

Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma
por: Liu, Lulu, et al.
Publicado: (2023)

Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis
por: Zhang, Peng-Fei, et al.
Publicado: (2023)

Chinese herbal medicine combined with oxaliplatin-based chemotherapy for advanced gastric cancer: A systematic review and meta-analysis of contributions of specific medicinal materials to tumor response
por: Tan, Ying, et al.
Publicado: (2022)

Antitumor effect of Kanglaite® injection in human pancreatic cancer xenografts
por: Liu, Ying, et al.
Publicado: (2014)

First-line chemotherapy for ovarian cancer – the controversy continues
por: Kaye, S B
Publicado: (2002)

Intraarterial chemotherapy as the first-line therapy in penile cancer
por: Chiang, P-H, et al.
Publicado: (2014)

Adjuvant and first line chemotherapy use for endometrial cancer
por: Knisely, Anne, et al.
Publicado: (2022)

First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis
por: Möhring, Christian, et al.
Publicado: (2021)

Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy
por: Fiteni, Frédéric, et al.
Publicado: (2014)

Cost‐effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first‐line treatment for advanced esophageal cancer
por: Ye, Zhuo‐Miao, et al.
Publicado: (2022)

Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract cancer in China
por: Zheng, Zhiwei, et al.
Publicado: (2023)

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma: a cost-effectiveness analysis
por: Cao, Xueqiong, et al.
Publicado: (2023)

First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis
por: Landre, Thierry, et al.
Publicado: (2020)

First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)
por: Kato, Ken, et al.
Publicado: (2022)

A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea
por: Lee, Hee Seung, et al.
Publicado: (2017)

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
por: Vasey, P A, et al.
Publicado: (2001)

First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma
por: Bongiovanni, Alberto, et al.
Publicado: (2015)

Outcomes of first line chemotherapy in patients with chronic lymphocytic leukemia
por: Nazir, Adil, et al.
Publicado: (2016)

Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First‐Line Gastric Cancer and Elevated Plasma VEGF‐A
por: Han, K, et al.
Publicado: (2016)

Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC
por: Rizvi, Naiyer, et al.
Publicado: (2015)

Efficacy and safety of Kanglaite injection combined with chemotherapy for women breast cancer: A protocol for systematic review and meta-analysis of randomized clinical trials
por: Cheng, Shengli, et al.
Publicado: (2021)

Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study
por: Zhang, Yan, et al.
Publicado: (2022)

Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis
por: Citterio, Chiara, et al.
Publicado: (2018)

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
por: Yamamoto, Shun, et al.
Publicado: (2021)

Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study
por: Babu, K Govind, et al.
Publicado: (2014)

Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer
por: Ye, Zhuo-miao, et al.
Publicado: (2023)

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial
por: Wang, Jie, et al.
Publicado: (2021)

Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China
por: Chen, Ting, et al.
Publicado: (2022)

First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States
por: Liu, Wenjie, et al.
Publicado: (2023)

First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer.
por: Athanassiou, A. E., et al.
Publicado: (1989)

First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence.
por: Sandercock, J., et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_pghc5t9tmrmvrnmht7nv4v0cp0